Circulating miR-19b-3p as a Novel Prognostic Biomarker for Acute Heart Failure.
Yang Su,Yuxi Sun,Yansong Tang,Hao Li,Xiaoyu Wang,Xin Pan,Weijing Liu,Xianling Zhang,Fenglei Zhang,Yawei Xu,Chunxi Yan,Sang‐Bing Ong,Dachun Xu
DOI: https://doi.org/10.1161/jaha.121.022304
IF: 6.106
2021-10-07
Journal of the American Heart Association
Abstract:Background Circulating microRNAs are emerging biomarkers for heart failure (HF). Our study aimed to assess the prognostic value of microRNA signature that is differentially expressed in patients with acute HF. Methods and Results Our study comprised a screening cohort of 15 patients with AHF and 5 controls, a PCR‐discovery cohort of 50 patients with AHF and 26 controls and a validation cohort of 564 patients with AHF from registered study DRAGON‐HF (Diagnostic, Risk Stratification and Prognostic Value of Novel Biomarkers in Patients With Heart Failure). Through screening by RNA‐sequencing and verification by reverse‐transcription quantitative polymerase chain reaction, 9 differentially expressed microRNAs were verified (miR‐939‐5p, miR‐1908‐5p, miR‐7706, miR‐101‐3p, miR‐144‐3p, miR‐4732‐3p, miR‐3615, miR‐484 and miR‐19b‐3p). Among them, miR‐19b‐3p was identified as the microRNA signature with the highest fold‐change of 8.4 and the strongest prognostic potential (area under curve with 95% CI, 0.791, 0.654–0.927). To further validate its prognostic value, in the validation cohort, the baseline level of miR‐19b‐3p was measured. During a follow‐up period of 19.1 (17.7, 20.7) months, primary end point comprising of all‐cause mortality or readmission due to HF occurred in 48.9% patients, while patients in the highest quartile of miR‐19b‐3p level presented the worst survival (Log‐rank P <0.001). Multivariate Cox model showed that the level of miR‐19b‐3p could independently predict the occurrence of primary end point (adjusted hazard ratio,1.39; 95% CI, 1.18–1.64). In addition, miR‐19b‐3p positively correlated with soluble suppression of tumorigenicity 2 and echocardiographic indexes of left ventricular hypertrophy. Conclusions Circulating miR‐19b‐3p could be a valuable prognostic biomarker for AHF. In addition, a high level of circulating miR‐19b‐3p might indicate ventricular hypertrophy in AHF subjects. Registration URL: https://www.clinicaltrials.gov. Unique Identifier: NCT03727828. Nonstandard Abbreviations and Acronyms AHF acute heart failure HFpEF heart failure with preserved ejection fraction IVST interventricular septal thickness LVMI left ventricular mass index LVPWT left ventricular posterior wall thickness NYHA New York Heart Association sST2 soluble suppression of tumorigenicity 2 Clinical Perspective What Is New? miR‐19b‐3p is identified as a novel prognostic microRNA signature for acute heart failure population. The baseline level of miR‐19b‐3p was strongly correlated with echocardiographic indexes of left ventricular hypertrophy and the fibrosis‐related biomarker soluble suppression of tumorigenicity 2. What Are the Clinical Implications? The expression level of miR‐19b‐3p at the onset of acute heart failure could predict the prognosis and function as a potential biomarker for stratification of patients with acute heart failure. The association of miR‐19b‐3p with hypertrophic and fibrosis indexes prompts for further investigations to reveal the pathogenesis of acute heart failure. Acute heart failure (AHF) is a severe cardiac syndrome that carries a high risk of hospital readmission and mortality. Predicting the outcome of patients with AHF has been a challenging task. Although various circulating peptides, such as natriuretic peptides, have been shown to facilitate the diagnosis and guidance of short and long term therapy in patients with AHF their drawbacks limit their potential as prognostic biomarkers. Recently, microRNAs (miRNAs) have been gaining attention due to their promising role as potential biomarkers for stratifying patients with cardiac diseases. 1 miRNAs are small non‐coding RNAs that orchestrate homeostasis through acting on post‐transcription process. Due to their considerable stability, circulating miRNAs have been promoted as ideal biomarkers for heart failure (HF). 2 -Abstract Truncated-
cardiac & cardiovascular systems